Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Persistence With Injectable Antidiabetic Agents In Members With Type 2 Diabetes In A Commercial Managed Care Organization

C. Cooke, H. Y. Lee, Y. P. Tong, S. Haines
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Abstract Objective: While many patients with type 2 diabetes require insulin to achieve glycemic goals, little is known about patients’ persistence with insulin or other injectable antidiabetic therapies. The objective of this study was to evaluate persistence with injectable antidiabetic agents in patients with type 2 diabetes who were naïve to these treatments. Methods: The study cohort was obtained using administrative and pharmacy claims data from a commercial managed care organization of approximately 1.2 million members with pharmacy benefits. The inclusion criteria were members with type 2 diabetes who had at least one pharmacy claim for insulin glargine, insulin detemir, exenatide, or isophane insulin human (NPH insulin) from January 1, 2006 through June 30, 2006. The first claim for any of these injectable therapies was considered the index prescription. Members were excluded if they filled a prescription (a) for any injectable antidiabetic medication from July 2005 through December 2005; or (b) for short/rapid-acting or mixed insulins during 2006, either prior to the index date or within 30 days following the index date. The primary outcome was persistence with the index drug, defined as number of months between the initiation of therapy (i.e., index date) and either the end of therapy (date of last fill plus days supply) or study period of 12 months. The secondary outcome was the percentage of patients with claims for new antidiabetic agents added after index date. Multivariate regression with life data (survival analysis) was performed with number of months of persistence as the dependent variable. Results: The cohort consisted of 1769 members with a mean (SD) age of 53.2 (12.5) years and 47.4% were men. Mean (SD) months of persistence for members on insulin glargine, insulin detemir and exenatide were similar at 7.8 (4.1), 7.8 (4.4), and 7.6 (4.4), respectively. Members taking NPH insulin had statistically lower persistence at 5.6 (4.5) months (P < 0.001). Overall persistence was 28.7% for injectable antidiabetics at 1 year among treatment-naïve patients. In a multivariate regression model, patients who were younger (P = 0.025) and who initially received NPH insulin (P < 0.001) were less likely to persist. There was no association between persistence and sex, initial copayment, or number of oral antidiabetic medications at time of index prescription. Members in the exenatide and NPH insulin groups were less likely to receive new antidiabetic agents compared with the insulin glargine group (P < 0.001). Limitations include the use of pharmacy claims to proxy the type of diabetes and patients with gestational diabetes may have been included. Missing or inaccurate claims data, the use of samples and hospitalizations may have occurred and would result in an underestimation of persistence. Conclusions: Persistence was low for injectable antidiabetics at 1 year among treatment-naïve patients. Patients who received insulin glargine, insulin detemir, or exenatide were more likely to persist than patients receiving NPH insulin. Older patients were more likely to persist, but sex, copayment and number of oral antidiabetic medications at initiation of the injectable antidiabetic were not associated with persistence.
This paper references
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes
L. Kennedy (2007)
The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
M. Riddle (2003)
Standards of Medical Care in Diabetes—2008
I. Hirsch (2008)
Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
J. Rosenstock (2001)
Problems paying out-of-pocket medication costs among older adults with diabetes.
J. Piette (2004)
Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.
R. Balkrishnan (2003)
Utilization of oral hypoglycemic agents in a drug-insured U.S. population.
S. Boccuzzi (2001)
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
K. Horvath (2007)
Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report.
Carol E. Koro (2004)
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
R. Heine (2005)
A systematic review of adherence with medications for diabetes.
J. Cramer (2004)
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
R. Holman (2007)
Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine.
Tiffany N Erickson (2006)
Effect of Increased Cost-Sharing on Oral Hypoglycemic Use in Five Managed Care Organizations: How Much Is Too Much?
D. Roblin (2005)
Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
M. Peyrot (2005)
Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.
L. Donnelly (2007)
National diabetes fact sheet: general information and national estimates on diabetes in the United States
Resistance to Insulin Therapy Among Patients and Providers Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study
M. Peyrot (2005)
The treat-to-target trial
MC Riddle (2003)
et al., for the GWAA study group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes
RJ Heine (2005)
The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review
J. Cramer (2008)
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes
P. Cryer (2007)

This paper is referenced by
Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
S. Kalirai (2017)
A comparison of duration of first prescribed insulin therapy in uncontrolled type 2 diabetes.
G. Hall (2011)
Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden
B. Eliasson (2020)
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
M. Davies (2017)
Treatment persistence behaviours in patients with type 2 diabetes (T2DM) after initiation of basal insulin: An exploratory analysis from a Spanish real-world sample
Miriam Rubio de Santos (2019)
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
R. Henry (2014)
Recent Publications on Medications and Pharmacy
Jacyntha A. Sterling (2009)
Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US
M. Perez-Nieves (2016)
Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States
S. Kalirai (2020)
Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes
S. Ross (2011)
Injectable therapy in type 2 diabetes mellitus: strategies to improve therapeutic adherence
Olga Gurova (2019)
A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures
M. Bonafede (2010)
Treatment Modifications and Medical Costs Associated with Use of Exenatide BID or Insulin Glargine in Type 2 Diabetes Patients: A Retrospective Database Analysis
M. Bonafede (2013)
Oral semaglutide in type 2 diabetes.
Sarah L Anderson (2020)
Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
R. Henry (2013)
Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey
M. Perez-Nieves (2017)
Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment
D. Kruger (2015)
Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study
Simon Zhornitsky (2015)
A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
R. Henry (2013)
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial
S. Bain (2019)
Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study
Jieling Chen (2020)
Real-world insulin treatment persistence among patients with type 2 diabetes.
W. Wei (2014)
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
S. T. Buckley (2018)
Adherence to Therapies in Patients with Type 2 Diabetes
L. García-Pérez (2013)
Pharmacokinetic and dose‐finding studies on efpeglenatide in patients with type 2 diabetes
K. Yoon (2020)
Correlates of basal insulin persistence among insulin-naïve people with type 2 diabetes: results from a multinational survey
M. Peyrot (2017)
Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
S. Davis (2011)
The factors associated with insulin nonpersistence in persons with type 2 diabetes.
Fu-Shun Yen (2020)
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
R. Pettis (2011)
Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes.
C. V. Spain (2016)
Medication Possession and Glycemic Control Among Uninsured Type 2 Diabetics
Wesley Ward (2012)
The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review
J. Best (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar